---
figid: PMC6094676__mmt-02-133-g1
figlink: /pmc/articles/PMC6094676/figure/F0001/
number: <b>Figure 1.</b>
caption: 'Activation of KIT, a receptor tyrosine kinase, leads to dual activation
  of the MAPK (NRAS, BRAF, MEK, ERK) and PI3K signaling pathways. The MAPK signaling
  pathway results in cell proliferation by activating cyclin-CDK complexes that promote
  cell cycle progression and gene transcription, as well as by influencing other transcriptional
  regulators. Signal output through the PI3K pathway leads to antagonism of apoptosis
  and increased cell growth and proliferation. The varying sizes of each protein in
  this figure are relative to the percentage of 262 cutaneous melanomas (the latest
  from The Cancer Genome Atlas dataset) that harbor alterations (mutations, amplifications,
  homozygous deletions and mRNA up/downregulation) in each protein''s respective encoding
  gene. For example, BRAF is the largest because the BRAF gene has the highest burden
  of alterations among the 262 melanoma samples. Small-molecule, targeted therapies
  are listed next to target proteins. The following protein–gene associations were
  used when extracting data from the cancer genome atlas (those not listed share the
  same name): MEK–MAP2K1/2, ERK–MAPK3/1, Cyclin D1–CCND1, PI3K–PI3KCA, AKT–AKT3, p53–TP53,
  BIM–BCL2L11. Additionally, p14ARF and p16INK4A are alternative splice products of
  the same gene, CDKN2A.†Drugs approved by the US FDA for treatment of advanced melanoma.'
pmcid: PMC6094676
papertitle: Oncogene-directed small molecule inhibitors for the treatment of cutaneous
  melanoma.
reftext: Philip Eliades, et al. Melanoma Manag. 2015 May;2(2):133-147.
pmc_ranked_result_index: '28702'
pathway_score: 0.9284402
filename: mmt-02-133-g1.jpg
figtitle: Oncogene-directed small molecule inhibitors for the treatment of cutaneous
  melanoma
year: '2015'
organisms: Homo sapiens
ndex: df62ce1b-df0b-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6094676__mmt-02-133-g1.html
  '@type': Dataset
  description: 'Activation of KIT, a receptor tyrosine kinase, leads to dual activation
    of the MAPK (NRAS, BRAF, MEK, ERK) and PI3K signaling pathways. The MAPK signaling
    pathway results in cell proliferation by activating cyclin-CDK complexes that
    promote cell cycle progression and gene transcription, as well as by influencing
    other transcriptional regulators. Signal output through the PI3K pathway leads
    to antagonism of apoptosis and increased cell growth and proliferation. The varying
    sizes of each protein in this figure are relative to the percentage of 262 cutaneous
    melanomas (the latest from The Cancer Genome Atlas dataset) that harbor alterations
    (mutations, amplifications, homozygous deletions and mRNA up/downregulation) in
    each protein''s respective encoding gene. For example, BRAF is the largest because
    the BRAF gene has the highest burden of alterations among the 262 melanoma samples.
    Small-molecule, targeted therapies are listed next to target proteins. The following
    protein–gene associations were used when extracting data from the cancer genome
    atlas (those not listed share the same name): MEK–MAP2K1/2, ERK–MAPK3/1, Cyclin
    D1–CCND1, PI3K–PI3KCA, AKT–AKT3, p53–TP53, BIM–BCL2L11. Additionally, p14ARF and
    p16INK4A are alternative splice products of the same gene, CDKN2A.†Drugs approved
    by the US FDA for treatment of advanced melanoma.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MTOR
  - NF1
  - MAP2K2
  - MAPK3
  - BRAF
  - MDM2
  - MDM4
  - MAP2K1
  - PIK3R3
  - NRAS
  - CDKN2A
  - BCL2
  - CDK4
  - MAPK1
  - PIK3R6
  - GSK3B
  - KIT
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - BCL2L11
  - BAD
  - PTEN
  - RPS6KA1
  - PIK3R5
  - PIK3R4
  - TP53
  - AKT3
  - AKT1
  - PIK3CA
  - AKT2
  - Temsirolimus
  - Nilotinib
  - Imatinib Masatinib
  - BEZ235
  - Trametinib
  - Cobimetinib
  - Cancer
  - Lung cancer
  - Melanoma
genes:
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: NF1
  symbol: NF1
  source: hgnc_symbol
  hgnc_symbol: NF1
  entrez: '4763'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MDM2
  symbol: MDM2
  source: hgnc_symbol
  hgnc_symbol: MDM2
  entrez: '4193'
- word: MDM4
  symbol: MDM4
  source: hgnc_symbol
  hgnc_symbol: MDM4
  entrez: '4194'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: P14ARF
  symbol: p14ARF
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: BCL2
  symbol: BCL2
  source: hgnc_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: P16INK4A
  symbol: p16INK4a
  source: hgnc_alias_symbol
  hgnc_symbol: CDKN2A
  entrez: '1029'
- word: CDK4
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: GSK3B
  symbol: GSK3B
  source: hgnc_symbol
  hgnc_symbol: GSK3B
  entrez: '2932'
- word: KIT
  symbol: KIT
  source: hgnc_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: BIM
  symbol: BIM
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2L11
  entrez: '10018'
- word: BAD
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RPS6KA1
  symbol: RPS6KA1
  source: hgnc_symbol
  hgnc_symbol: RPS6KA1
  entrez: '6195'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Nilotinib
  source: MESH
  identifier: C498826
- word: Imatinib Masatinib
  source: MESH
  identifier: C526575
- word: BEZ235
  source: MESH
  identifier: C531198
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Melanoma
  source: ''
  identifier: ''
---
